Staff (FBX), General Services Administration, Washington, DC 20406. Attn: **Federal Register** Notice. GSA will consider your comments in developing the final move management services provisions. In the interim, rates filed in response to GSA's 1996 Request for Offers have been extended for 90 days from October 31, 1997 to January 29, 1998.

FOR FURTHER INFORMATION CONTACT: Larry Tucker, Senior Program Analyst, Travel and Transportation Management Staff, FSS/GSA, 703–305–7660.

SUPPLEMENTARY INFORMATION: The proposed changes appear at 62 FR 64225, December 4, 1997.

Dated: December 22, 1997.

Janice Sandwen,

Director, Travel and Transportation Management Staff.

[FR Doc. 97–33862 Filed 12–29–97; 8:45 am]

BILLING CODE 6820–24–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Notice of Three Meetings of the National Bioethics Advisory Commission (NBAC) and its Subcommittees

SUMMARY: Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is given of three meetings of the National Bioethics Advisory Commission and its subcommittees. The Commission will continue addressing the protection of the rights and welfare of human subjects in research including decisionally impaired populations and the federal agency survey as well as issues in genetics including genetics information and tissue storage. The meetings are open to the public and opportunities for statements by the public will be provided.

Dates, Times, and Locations

Genetics Subcommittee: January 6, 1998, 1:30 pm–5:00 pm, Crystal Gateway Marriott Hotel, 1700 Jefferson Davis Highway, Arlington, Virginia

Full Commission: January 7, 1998, 8:00 am–5:00 pm, Crystal Gateway Marriott Hotel, 1700 Jefferson Davis Highway, Arlington, Virginia

Human Subjects Subcommittee: January 8, 1998, 8:00 am—12:30 pm, Crystal Gateway Marriott Hotel, 1700 Jefferson Davis Highway, Arlington, Virginia

SUPPLEMENTARY INFORMATION: The President established the National Bioethics Advisory Commission (NBAC) by Executive Order 12975 on October 3, 1995. The mission of the NBAC is to advise and make recommendations to the National Science and Technology Council and other entities on bioethical issues arising from the research on human biology and behavior, and in the applications of that research including clinical applications.

Public Participation

The meetings are open to the public with attendance limited by the availability of space. Members of the public who wish to present oral statements should contact Ms. Patricia Norris by telephone, fax machine, or mail as shown below prior to the meeting as soon as possible. The Chairs of the full Commission and subcommittees will reserve time for presentations by persons requesting to speak. The order of speakers will be assigned on a first come, first serve basis. Individuals unable to make oral presentations are encouraged to mail or fax their comments to the NBAC staff office at least four business days prior to the meeting for distribution to the subcommittee members or Commission and inclusion in the public record. Persons needing special assistance, such as sign language interpretation or other special accommodations, should contact NBAC staff at the address or telephone number listed below as soon as possible.

FOR FURTHER INFORMATION CONTACT: Ms. Patricia Norris, National Bioethics Advisory Commission, MSC–7508, 6100 Executive Boulevard, Suite 5B01, Rockville, Maryland 20892–7508, telephone 301–402–4242, fax number 301–480–6900.

Henrietta D. Hyatt-Knorr,

Deputy Executive Director, National Bioethics Advisory Commission.

[FR Doc. 97–33792 Filed 12–29–97; 8:45 am]

BILLING CODE 4160–17–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Orphan Products Board; Notice of Public Meeting

AGENCY: Office of Public Health and Science.

ACTION: Notice of meeting.

SUMMARY: The Department of Health and Human Services and the Office of Public Health and Science (Office of the Assistant Secretary for Health) are announcing a public meeting of the Orphan Products Board. The purpose of this meeting is to facilitate the research, development, and approval of orphan products and to coordinate Government activities with the private sector to achieve these goals. In this meeting there will be an opportunity for interested persons to present information and views on the issue of orphan products development.

DATES: The public meeting be held on Thursday, February 12, 1998, from 2 p.m. to 5 p.m. Requests to attend or participate should be sent by February 4, 1998.

ADDRESSES: The public meeting will be held at the Hubert H. Humphrey Bldg., 200 Independence Ave. S.W., Washington, DC. Written requests to attend or participate should be sent to Robert F. Steeves, Orphan Products Board, Food and Drug Administration (HF–35), 5600 Fishers Lane, rm. 8–73, Rockville, MD 20857, FAX 301–443–4915. Requests from nongovernmental persons should include full name, address, affiliation, and social security number for use in obtaining security clearance for entry into the facility.

FOR FURTHER INFORMATION CONTACT: Robert F. Steeves, Orphan Products Board, Food and Drug Administration (HF–35), 5600 Fishers Lane, Rockville, MD 20857, 301–827–3666.

SUPPLEMENTARY INFORMATION: An orphan drug is a drug for the treatment of a rare disease or condition which either has: (1) A prevalence in the United States of under 200,000 persons; or (2) a higher prevalence and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug for such disease or condition will be recovered from sales in the United States of such drug. The Orphan Drug Act (Pub. L. 97–414) enacted on January 4, 1983, as amended, established a number of incentives to encourage the development and marketing of orphan drugs.

The Orphan Drug Act also established an Orphan Products Board to promote the development of drugs and devices for rare diseases or conditions and to assure appropriate coordination among interested Federal agencies, manufacturers, and organizations representing patients with rare diseases.

The Orphan Products Board is chaired by the Assistant Secretary for Health. The Board is composed of representatives from the Department of Health and Human Services (DHHS), the Department of Veterans Affairs (DVA), The National Institute of Disability and Rehabilitation Research (NIDRR), the Social Security Administration (SSA), and the Department of Defense (DOD). Within DHHS, representatives from the